Michael Sapienza: Urgent Mission to End Colorectal Cancer
Michael Sapienza/LinkedIn

Michael Sapienza: Urgent Mission to End Colorectal Cancer

Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared a post on LinkedIn:

“Colorectal Cancer is the deadliest cancer in adults under 50 and we’ve had enough…

The Colorectal Cancer Alliance is seeking an accomplished and strategic Chief Development Officer (CDO) to lead a bold new chapter of growth and impact. One that has a huge focus on Social Impact around a Project Cure scientific ecosystem to find new treatments for colorectal cancer.

This executive will play a critical role in scaling revenue from $21M to $60M within three years, while strengthening a high-performing, donor-centric culture of philanthropy across the organization.

Reporting to the CEO and partnering closely with the Executive Team and Board of Directors, the CDO will oversee a comprehensive development strategy spanning non traditional funding sources like a Social Impact or Social Investment Fund, AI and big tech brands as well as the traditional revenue streams of corporate, foundation and industry giving, individual philanthropy, and community-based fundraising.

As a hands-on leader, they will also source, steward, and manage a portfolio of high-capacity donors, securing transformational six and seven-figure investments.

The ideal candidate brings a proven track record of driving significant revenue growth in a complex, mission-driven organization, along with deep experience leading high-performing teams, executing large-scale campaigns, and building strong relationships with donors, partners, and stakeholders.

This is a unique opportunity to help lead the Alliance’s $100M Project Cure CRC campaign and accelerate progress toward ending colorectal cancer as we know it. If you are ready to lead transformational growth, create and close bold gifts, build elite teams, and scale impact nationwide, we want to hear from you.”

Other articles about Colorectal Cancer on OncoDaily.